Biota Pharmaceuticals

The Company has four product candidates in development that address viral infections that have limited therapeutic options.
We are currently enrolling patients for the Phase 2b SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. Our second Phase 2 clinical product candidate is BTA074 (AP611074), a novel topical treatment for genital warts caused by HPV types 6 & 11. We also are developing BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections. We anticipate beginning a Phase 1 clinical trial with BTA-C585 in Q3 2105. Laninamivir octanoate, a one-time, inhaled neuraminidase for the treatment of influenza A and B infections has completed a global Phase 2 trial. 
In addition to our research and development activities, we receive royalty revenue from two approved neuraminidase inhibitors: zanamivir, marketed worldwide as Relenza® by GlaxoSmithKline; and LANI, marketed in Japan as Inavir® by Daiichi-Sankyo.

Type
Public
HQ
Alpharetta, US
Founded
1984
Size (employees)
19 (est)
Biota Pharmaceuticals was founded in 1984 and is headquartered in Alpharetta, US

Biota Pharmaceuticals Office Locations

Biota Pharmaceuticals has an office in Alpharetta
Alpharetta, US (HQ)
100 2500 Northwinds Pkwy

Biota Pharmaceuticals Data and Metrics

Biota Pharmaceuticals Financial Metrics

Biota Pharmaceuticals's revenue was reported to be $9.3 m in FY, 2016 which is a 62% decrease from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

9.3 m

Revenue growth (FY, 2015 - FY, 2016), %

(62%)

Net income (FY, 2016)

(25.4 m)

EBIT (FY, 2016)

(25.2 m)

Cash (31-Dec-2016)

49.7 m
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Revenue

68.7 m24.6 m9.3 m

Revenue growth, %

(64%)(62%)

Cost of goods sold

51.1 m3.6 m

Gross profit

17.6 m21 m

Gross profit Margin, %

26%85%

Operating expense total

80.2 m44.1 m34.5 m

EBIT

(11.5 m)(19.5 m)(25.2 m)

EBIT margin, %

(17%)(79%)(271%)

Net Income

(11 m)(19.1 m)(25.4 m)
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Cash

81.7 m44.7 m49.7 m

Current Assets

101.1 m70.8 m72.4 m

PP&E

2 m200 k300 k

Total Assets

114 m79.4 m72.7 m

Accounts Payable

2.8 m1.9 m3.9 m

Current Liabilities

26.9 m9 m9.2 m

Additional Paid-in Capital

146.4 m155.6 m157.6 m

Retained Earnings

(89.8 m)(108.9 m)(134.3 m)

Total Equity

86.9 m69.5 m46.2 m

Financial Leverage

1.3 x1.1 x1.6 x
Numbers are in $, USDFY, 2014FY, 2015FY, 2016

Net Income

(11 m)(19.1 m)(25.4 m)

Depreciation and Amortization

2.4 m1.1 m100 k

Accounts Receivable

(7.1 m)6.2 m11.9 m

Cash From Operating Activities

(3.3 m)(9.6 m)(14.1 m)

Purchases of PP&E

(100 k)(100 k)(200 k)

Cash From Investing Activities

(10.1 m)(19.4 m)1.3 m

Cash From Financing Activities

26.8 m(100 k)17.8 m
Numbers are in $, USDY, 2016

Revenue/Employee

489.5 k

Financial Leverage

1.6 x

Biota Pharmaceuticals Operating Metrics

FY, 2016

Phase II Trials

4

Marketed

2

Biota Pharmaceuticals Company Life and Culture

You may also be interested in